Cue Biopharma announces USD 50 million private placement of unregistered shares and pre-funded warrants

Cue Biopharma, Inc.

Cue Biopharma, Inc.

CUE

0.00
  • Cue Biopharma priced a USD 50 million private placement of unregistered equity to accredited investors, expected to close around July 13, 2026.
  • Deal includes 1,418,071 common shares at USD 33.21 each, with 87,500 pre-funded warrants offered to certain investors at USD 33.209.
  • Pre-funded warrants carry a USD 0.001 exercise price, are immediately exercisable, with no expiration until fully exercised.
  • Cormorant Asset Management led the financing; Columbia Threadneedle Investments participated.
  • Proceeds earmarked for clinical development funding, with remaining funds for general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.